Compare FHB & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHB | DYN |
|---|---|---|
| Founded | 1858 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 2016 | 2020 |
| Metric | FHB | DYN |
|---|---|---|
| Price | $24.80 | $17.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 17 |
| Target Price | $28.89 | ★ $34.33 |
| AVG Volume (30 Days) | ★ 2.5M | 2.4M |
| Earning Date | 10-23-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ 22.91 | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $880,788,000.00 | N/A |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $56.09 | N/A |
| P/E Ratio | $14.78 | ★ N/A |
| Revenue Growth | ★ 8.94 | N/A |
| 52 Week Low | $23.26 | $14.00 |
| 52 Week High | $30.58 | $27.31 |
| Indicator | FHB | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 49.96 |
| Support Level | $24.19 | $16.65 |
| Resistance Level | $25.42 | $17.31 |
| Average True Range (ATR) | 0.48 | 0.96 |
| MACD | -0.07 | 0.11 |
| Stochastic Oscillator | 15.31 | 47.09 |
First Hawaiian Inc is a bank holding company. It provides a diversified range of banking services to consumer and commercial customers, including deposit products, lending services, and wealth management and trust services. The company offers a variety of deposit products to its customers, including checking and savings accounts and other types of deposit accounts. It provides commercial and industrial lending, including auto dealer flooring, commercial real estate, and construction lending. It also offers comprehensive consumer lending services focused on residential real estate lending, indirect auto financing, and other consumer loans. The company's segments are Retail Banking, Commercial Banking, and Treasury, and others of which key revenue is derived from Retail Banking.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.